C Dahlof
Overview
Explore the profile of C Dahlof including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
1021
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tfelt-Hansen P, Bjarnason N, Dahlof C, Derry S, Loder E, Massiou H
Cephalalgia
. 2008 May;
28(7):683-8.
PMID: 18498392
Tolerability of a drug should be regarded as important as its efficacy. In all four phases of drug development evaluation of adverse events is important. Recommendations for assessment of adverse...
2.
Linde M, Mellberg A, Dahlof C
Cephalalgia
. 2006 May;
26(6):712-21.
PMID: 16686911
This study was designed to document prospectively and explore scientifically the natural course of untreated migraine attacks in detail. A new, integrated, time-intensity method for self-assessment of the intensity of...
3.
Linde M, Mellberg A, Dahlof C
Cephalalgia
. 2006 Jan;
26(2):113-21.
PMID: 16426264
Over the years the paradigm of treating early during the migraine attack has become well established in clinical practice. It is also recommended that the 5-HT(1B/1D) agonists be administered early...
4.
Dahlof C, Lines C
Expert Opin Investig Drugs
. 2005 Jul;
8(5):671-85.
PMID: 15992122
Rizatriptan (MAXALT MK-0462) is a new 5-HT(1B/1D) receptor agonist for the acute treatment of migraine. The marketed 10 mg and 5 mg oral doses are rapidly and consistently effective in...
5.
Linde M, Fjell A, Carlsson J, Dahlof C
Cephalalgia
. 2004 Dec;
25(1):41-7.
PMID: 15606569
The objectives were to introduce a new method for controlled trials of acupuncture in the field of headache research and to examine the role of needling per se. Women with...
6.
Linde M, Dahlof C
Cephalalgia
. 2004 May;
24(6):455-65.
PMID: 15154855
The authors have earlier reported a 1-year prevalence of 13.2 +/- 1.9% for migraine in Sweden. This is a subsequent extensive postal survey of the burden of disease and attitudes...
7.
Linde M, May A, Limmroth V, Dahlof C
Cephalalgia
. 2003 Sep;
23(7):491-5.
PMID: 12950373
Randomized placebo-controlled clinical trials have been the 'golden standard' during the last decades in the development of new drug therapies. This scientifically valid approach has recently been questioned in the...
8.
Farkkila M, Olesen J, Dahlof C, Stovner L, Bruggen J, Rasmussen S, et al.
Cephalalgia
. 2003 Jun;
23(6):463-71.
PMID: 12807526
To determine the tolerability and efficacy of eletriptan in patients who had discontinued oral sumatriptan due to lack of efficacy or intolerable adverse events (AEs) during previous clinical treatment (not...
9.
Stark R, Dahlof C, Haughie S, Hettiarachchi J
Cephalalgia
. 2002 May;
22(1):23-32.
PMID: 11993610
The efficacy, safety and tolerability of the 5-HT1B/D receptor agonist eletriptan (40 mg and 80 mg) in acute treatment of migraine was evaluated in a multinational, randomized, double-blind, parallel-group, placebo-controlled,...
10.